- Home
- RNAZ vs EVAX Comparison
RNAZ vs EVAX Comparison
Compare RNAZ & EVAX Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
Company Overview
Basic Information| Metric | RNAZ | EVAX |
|---|---|---|
| Founded | 2016 | 2008 |
| Country | United States | Denmark |
| Employees | N/A | N/A |
| Industry | Biotechnology: Pharmaceutical Preparations | Biotechnology: Biological Products (No Diagnostic Substances) |
| Sector | Health Care | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 27.9M | 27.5M |
| IPO Year | 2021 | 2020 |
Fundamental Metrics
Financial Performance| Metric | RNAZ | EVAX |
|---|---|---|
| Price | $1.80 | $2.80 |
| Analyst Decision | | Strong Buy |
| Analyst Count | 0 | 4 |
| Target Price | N/A | ★ $11.25 |
| AVG Volume (30 Days) | ★ 50.3K | 41.7K |
| Earning Date | 08-14-2026 | 11-19-2026 |
| Dividend Yield | N/A | N/A |
| EPS Growth | N/A | ★ N/A |
| EPS | N/A | ★ N/A |
| Revenue | N/A | N/A |
| Revenue This Year | N/A | N/A |
| Revenue Next Year | N/A | N/A |
| P/E Ratio | ★ N/A | N/A |
| Revenue Growth | N/A | N/A |
| 52 Week Low | $1.52 | $2.72 |
| 52 Week High | $15.33 | $8.10 |
Technical Indicators
Market Signals| Indicator | RNAZ | EVAX |
|---|---|---|
| Relative Strength Index (RSI) | 45.70 | 34.37 |
| Support Level | $1.55 | N/A |
| Resistance Level | $2.39 | $3.62 |
| Average True Range (ATR) | 0.17 | 0.14 |
| MACD | 0.08 | -0.05 |
| Stochastic Oscillator | 68.29 | 15.89 |
Price Performance
Historical ComparisonAbout RNAZ TransCode Therapeutics Inc.
TransCode Therapeutics Inc is a clinical-stage biotechnology company engaged in the development of RNA-based therapeutics and immuno-oncology treatments for cancer. The company's lead candidate, TTX-MC138, targets microRNA-10b and has completed a Phase 1a clinical trial, while it is also advancing additional product candidates, including a cancer vaccine and an oncolytic immunotherapy platform.
About EVAX Evaxion Biotech
Evaxion AS is a clinical-stage TechBio company developing novel vaccines with its proprietary, clinically validated and scalable AI platform, AI-Immunology. The platform harnesses the power of artificial intelligence to decode the human immune system and develop novel vaccine candidates for cancer and infectious diseases for patients in the market. Evaxion has developed a clinical-stage oncology pipeline of novel personalised vaccines and a preclinical infectious disease pipeline in bacterial and viral diseases with high unmet medical needs. The group is committed to transforming patients' lives by providing inventive and targeted treatment options.